<DOC>
	<DOCNO>NCT00171470</DOCNO>
	<brief_summary>Study provide initial data ass safety efficacy tegaserod use patient dyspepsia treat proton pump inhibitor ( PPI 's ) heartburn .</brief_summary>
	<brief_title>The Role Tegaserod Therapy Management Dyspeptic Symptoms Female Patients Proton Pump Inhibitors Treatment Heartburn .</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female patient 18 year old . Selfreported presence symptom consistent dyspepsia ( include midupper abdominal discomfort characterize post prandial fullness , early satiety bloat ) Stable dose PPI therapy least 4 week History intestinal obstruction , symptomatic gallbladder disease , suspect sphincter Oddi dysfunction , abdominal adhesion . Evidence dyspeptic symptom relieve defecation and/or associate change frequency stool form . With current bothersome symptom heartburn . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>dyspepsia</keyword>
	<keyword>hearburn</keyword>
	<keyword>female</keyword>
	<keyword>PPI</keyword>
</DOC>